Amgen Inc.

Nanyang Technological University

Kirin-amgen, Inc.

Chuan-Fa Liu

Ulrich Feige

Janet C Cheetham

Benny C Askew

Derin C D'amico

Gordon Ng

Mark A Jarosinski

Yue-Sheng Li

Colin V Gegg

Qi Huang

Yuelie Lu

Thomas Storz

Thomas Charles Boone

David L Lacey

Jean Marie Gudas

Paul Kostenuik

Fupeng Li

The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.

Thrombopoietic compounds

The present invention is directed to a method of alkylating a thiol group (R&#x2014;S&#x2014;H) or seleno group (R&#x2014;Se&#x2014;H) in a target molecule wherein the method comprises: reacting a target molecule comprising at least one thiol group with a compound of formula (I) or (II): wherein R is an acetyl group or any other acyl group or is a group comprising any one of: or wherein R in formula (II) can also be an alkyl group; and wherein R' is selected from a group consisting of a hydrogen, a methyl group and an ethyl group. In certain cases, the described methods may be used to install acetylated lysine analogs in target molecules (e.g., peptides, proteins).

Method for modification of organic molecules

The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a univalent vehicle, including peptides conjugated to univalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.

Antagonists of the bradykinin B1 receptor

The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.

The present invention relates to certain biologically active peptides and conjugated peptides which can be used as therapeutics or prophylactics against diseases or conditions linked to B1 as the causative agent. In a preferred embodiment of the invention biologically active PEG-conjugated peptides are provided. In one aspect of the present invention, pharmacologically active PEG-conjugated peptides of the present invention are useful to treat inflammation or pain.

Antagonists of the brandykinin B1 receptor

Pharmacologically active compounds are prepared by (a) selecting at least one peptide that modulates the activity of AGP-3, (b) preparing a gene construct that comprises at least one said selected sequence, and (c) expressing the pharmacologically active compound in which an Fc domain is covalently linked to the selected peptide. The pharmacologic agent can be expressed in

Modified peptides as therapeutic agents

Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein

Growing community of inventors

Waltham, MA, United States of America

Chuan-Fa Liu